“Our study establishes the first UK data on CABSI rates and shows that the incidence of CABSI decreased following the implementation of Matching Michigan care bundle.” Sashikumar et al (2014).
Reference:
Sashikumar P, Ramadan G, Pattnayak S, O’Loughlin K, Abdalla E. (2014) PC.97 Incidence of Central-Line-Associated Bloodstream Infection (CABSI) Rates in a Neonatal Unit: 3 year observational study. Archives of Disease in Childhood. Fetal and Neonatal Edition. 99(Suppl 1), p.A69.
[ctt tweet=”CLABSI decrease following implementation of Matching Michigan care bundle http://ctt.ec/dcA9_+ @ivteam #ivteam” coverup=”dcA9_”]
Abstract:
AIM: To estimate the incidence of CABSI and the effect of implementing Matching Michigan care bundle.
METHOD: Retrospective analysis of CABSI rates in all neonates with central lines. The reported CABSI rates have varied between 3.2 to 21.8/ 1000 catheter days.(1) The NNAP data on the incidence of CABSI rates 1.8-3.1/1000 is low due to underreporting.(2) We at medway had signed up for the Matching Michigan project aimed at reducing CABSI. We established our baseline CABSI rates at 13.6/1000 catheter days with snap shot audit before implementing the Matching Michigan project in 2011 and our CABSI rates have been below 10/1000 catheter days for three consecutive years. We are the first unit to publish the CABSI rates over a three year period in United Kingdom. The results are as follows: fetalneonatal;99/Suppl_1/A69-c/T1T1T1 Abstract PC.97 Table Comparative indicators 2011 2012 2013 Patients 141 151 154 Gestation
CONCLUSIONS: Our study establishes the first UK data on CABSI rates and shows that the incidence of CABSI decreased following the implementation of Matching Michigan care bundle.
REFERENCES: Folgori L, et al. Arch Dis Child Fetal Neonatal Ed. 2013;98:F518-F523 Annual Report National Neonatal Audit Program 2012, RCPCH.
Other intravenous and vascular access resources that may be of interest (External links – IVTEAM has no responsibility for content).
- Guide for intravenous chemotherapy and associated vascular access devices from Macmillan.
- CancerUK IV chemotherapy information.
